SlideShare uma empresa Scribd logo
1 de 28
1 
Rare Disease Stakeholder Dynamics 
Paul Allen Camm Epstein
NUMBERS
Definition of a rare disease: <200,000 Americans 
Number of rare diseases: >6,800 
Americans with a rare disease: 25-30 million 
NIH Office of Rare Disease Research 
http://rarediseases.info.nih.gov/about-ordr/pages/31/frequently-asked-questions 
3 11/12/2014
Rising prices, additional options and increasing use of combination 
therapy drive costs higher. 
11/12/2014 
Before: High $ * Very Low Vol = Low $ 
After: High $ * Low Vol = Medium $
Specialty medications are growing in absolute dollars 
and percent of drug spend 
$235 billion (50%) 
2018 
$92 billion (30%) 
2012 
CVS Caremark, Insights 2014 
http://info.cvscaremark.com/insights2014/INSIGHTS%20Trend%202014-v2.pdf 
5 11/12/2014
METHODS 
6
Physicians 
Pulmonary Arterial 
Hypertension 
Payers 
Patients 
Payers 
Physicians 
Cystic Fibrosis 
Patients 
Physicians 
Hereditary 
Angiodema 
Payers 
Patients
STAKEHOLDERS
• Want to feel better, improved quality of life 
– Fewer symptoms of condition and fewer side effects of therapy 
– Easier to administer products 
• Willing to make tradeoffs between efficacy and convenience 
• Cost is often not a concern 
– Depends upon coverage, needs/wants and disposable income 
• PAPs and charitable foundations typically address any financial difficulties 
• Very well-informed 
– Often better informed than physicians not specializing in the 
condition 
• Share information with and supportive of other patients 
• Often emotional 
– Life-threatening 
– Familial impacting multiple family members 
9 
Patients
Physicians 
• Appeal denials when necessary 
• Test and treat aggressively 
• Prefer to prescribe proven therapies 
– Yet, sensitive to patient preferences 
• Receptive to tradeoffs between efficacy and 
improved QOL 
10
Nurses 
• Work through patient assistance programs 
• Provide most patient education 
• Work through most access issue 
11
Payers 
• They generally do not manage rare conditions aggressively, but… 
– Willing to select preferred products, increase restrictions and contract when 
there are multiple, poorly differentiated options 
• Especially when there are large cost differences and/or multiple options in the same 
class 
• Willing to relax, but not abandon, requirements for evidence 
• Encourage care delivered outside of centers and discount ‘center of 
excellence’ designations 
– Especially when there is a lack of evidence 
• Encourage use of oral formulations 
– Particularly when the costs are similar 
• Discourage use of combination therapy 
– Particularly when there is a lack of evidence 
• Critically evaluate clinical guidelines/consensus statements 
– Reject those not based on evidence 
• Frustrated by manufacturer pricing 
12
Medical Societies 
• Develop consensus statements/clinical guidelines 
• Advocate what they believe to be appropriate care 
– Cost-effective care is an emerging consideration 
13
Manufacturers 
• Charge high prices for some therapies 
– Particularly when the target patient population is very 
small 
– Particularly when there is a genetic marker 
• Find it difficult to enroll sufficient numbers of patients in 
clinical trials 
• Very supportive of Patient Assistance Programs (PAPs) 
– Work hard to ensure patient out-of-pocket costs are 
not a barrier for those unable to pay 
14
Purchasers 
• Watching specialty pharmacy spend rise 
• Asking for tighter controls 
– Want to avoid negative public relations 
• Shifting costs to patients 
15
Advocacy Organizations 
• Celebrate the entry of new options 
– Interpret new entrants as a sign of progress towards 
a cure 
• Supporting clinical guideline/consensus statement 
development 
• Supporting center of excellence designations 
16
INTERACTIONS
• Share intense bonds 
– Often social, informal relationships 
“I feel like they are family” 
• Frequent and sometimes long conversations 
– Patients ask questions and make requests 
18
19 
• Regularly bringing diverse stakeholders 
together 
• Facilitating dialogue and collaboration
DYNAMICS
21 
Access 
Restrictions 
Multiple 
Therapies 
Combination 
Therapy 
Multiple Drugs in 
Same Class 
Prescribing by 
non-KOLs 
Payer 
Preferences 
Multiple Routes of 
Administration 
Patient 
Preferences 
Physician 
Preferences 
Efficacy 
Safety 
Cost 
Patient Costs 
Diffusion of 
Care Sites 
Oral 
Therapies 
Centers of 
Excellence 
Designations 
Public 
Relations 
Very Low 
Prevalence 
Significant 
Unmet Needs 
Awareness/ 
Knowledge 
Consensus 
Statements/Clinical 
Guidelines 
Earlier 
Diagnosis/Treatment 
Better 
Outcomes 
Increased 
Utilization 
Higher Drug 
Prices 
Growing 
Spend/Trend 
Clinical Trial 
Enrollment 
Difficulties 
Lack of Comparative 
Effectiveness Research 
Reliance on Patient 
Assistance 
Enhanced Role of 
Nurses 
Patient-Physician 
Conversations 
Hope 
Benefit 
Design 
Patient-Provider 
Relations
PREDICTIONS
• Halo effect across rare conditions 
– Acceleration towards access restrictions tipping points 
• Debate and research on oral therapies 
– Cost-effectiveness 
– Patient preferences 
• New methods for studying combination therapies 
23
• Patient registries to aggregate experience 
• Growth in supply of and demand for patient assistance 
• Enhanced social media and collaboration capabilities 
– Enriching interpersonal communications 
24
IMPLICATIONS
• Success in crowded markets 
– Novel mechanisms of action 
– Improved ROA differentiation 
– Genetic markers/companion diagnostics 
– Premium pricing that is justified and sustainable 
• Price reductions when indications expand 
26
• Success in new markets 
– New therapies 
– Sufficient unmet need to yield ROI 
27
Currant Insights, LLC 
33 East Avenue 
Saratoga Springs, NY 12866 
Camm Epstein 
Managing Director 
(518) 429-0875 
camm@currantinsights.com 
Olson Research Group, Inc 
1020 Stony Hill Road, Suite 300 
Yardley, PA, 19067 
Paul Allen 
Executive Vice President 
(215) 499-0244 
pallen@olsonreserchpa.com

Mais conteúdo relacionado

Mais procurados

What are the essential design features of personal health records to improve ...
What are the essential design features of personal health records to improve ...What are the essential design features of personal health records to improve ...
What are the essential design features of personal health records to improve ...Elisavet Andrikopoulou
 
Discussion on Health Information Exchange and Length of Stay-WHITE 2014
Discussion on Health Information Exchange and Length of Stay-WHITE 2014Discussion on Health Information Exchange and Length of Stay-WHITE 2014
Discussion on Health Information Exchange and Length of Stay-WHITE 2014Peiyin Hung
 
Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)Grupo16011
 
Recruitment & Retention Presentation
Recruitment & Retention PresentationRecruitment & Retention Presentation
Recruitment & Retention PresentationCora Giddens
 
CER 2016 Hernandez patient engagement
CER 2016 Hernandez patient engagementCER 2016 Hernandez patient engagement
CER 2016 Hernandez patient engagementCTSI at UCSF
 
How to comment on a Cochrane review
How to comment on a Cochrane reviewHow to comment on a Cochrane review
How to comment on a Cochrane reviewTamara Rader
 
CER 2016 Nguyen ctsi collaborative research
CER 2016 Nguyen ctsi collaborative researchCER 2016 Nguyen ctsi collaborative research
CER 2016 Nguyen ctsi collaborative researchCTSI at UCSF
 
CER 2016 Dohan EQUIP
CER 2016 Dohan EQUIPCER 2016 Dohan EQUIP
CER 2016 Dohan EQUIPCTSI at UCSF
 
CER 2016 Phillips cer symposium pcori 2016 from 012716
CER 2016 Phillips cer symposium pcori 2016 from 012716CER 2016 Phillips cer symposium pcori 2016 from 012716
CER 2016 Phillips cer symposium pcori 2016 from 012716CTSI at UCSF
 
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsHow to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsTodd Berner MD
 
Palliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruPalliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruKesho Conference
 
Covering Cancer Treatments: Tricks of the Trade
Covering Cancer Treatments: Tricks of the TradeCovering Cancer Treatments: Tricks of the Trade
Covering Cancer Treatments: Tricks of the TradeIvan Oransky
 
Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...Nowgen
 
ICTS Case Studies
ICTS Case StudiesICTS Case Studies
ICTS Case StudiesGregg Sweet
 
Recruitment & Retention Plan: A Sample Strategy Presentation
Recruitment & Retention Plan: A Sample Strategy PresentationRecruitment & Retention Plan: A Sample Strategy Presentation
Recruitment & Retention Plan: A Sample Strategy PresentationMarwah Zagzoug, PhD
 
Site and Patient Engagement - Strategies for Improving Retention
Site and Patient Engagement - Strategies for Improving RetentionSite and Patient Engagement - Strategies for Improving Retention
Site and Patient Engagement - Strategies for Improving RetentionJohn Reites
 
Health information Seminar - Dr Derick Mitchell - Oct 2017
Health information Seminar - Dr Derick Mitchell - Oct 2017Health information Seminar - Dr Derick Mitchell - Oct 2017
Health information Seminar - Dr Derick Mitchell - Oct 2017ipposi
 
Cirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSION
Cirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSIONCirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSION
Cirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSIONKen Smith
 

Mais procurados (20)

What are the essential design features of personal health records to improve ...
What are the essential design features of personal health records to improve ...What are the essential design features of personal health records to improve ...
What are the essential design features of personal health records to improve ...
 
Discussion on Health Information Exchange and Length of Stay-WHITE 2014
Discussion on Health Information Exchange and Length of Stay-WHITE 2014Discussion on Health Information Exchange and Length of Stay-WHITE 2014
Discussion on Health Information Exchange and Length of Stay-WHITE 2014
 
Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)Roadmap to-choosing-a-medical-specialty- (1)
Roadmap to-choosing-a-medical-specialty- (1)
 
Recruitment & Retention Presentation
Recruitment & Retention PresentationRecruitment & Retention Presentation
Recruitment & Retention Presentation
 
CER 2016 Hernandez patient engagement
CER 2016 Hernandez patient engagementCER 2016 Hernandez patient engagement
CER 2016 Hernandez patient engagement
 
How to comment on a Cochrane review
How to comment on a Cochrane reviewHow to comment on a Cochrane review
How to comment on a Cochrane review
 
CER 2016 Nguyen ctsi collaborative research
CER 2016 Nguyen ctsi collaborative researchCER 2016 Nguyen ctsi collaborative research
CER 2016 Nguyen ctsi collaborative research
 
CER 2016 Dohan EQUIP
CER 2016 Dohan EQUIPCER 2016 Dohan EQUIP
CER 2016 Dohan EQUIP
 
CER 2016 Phillips cer symposium pcori 2016 from 012716
CER 2016 Phillips cer symposium pcori 2016 from 012716CER 2016 Phillips cer symposium pcori 2016 from 012716
CER 2016 Phillips cer symposium pcori 2016 from 012716
 
How to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World TrialsHow to Define Effective and Efficient Real World Trials
How to Define Effective and Efficient Real World Trials
 
Palliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weruPalliative care services into an existing oncology programme by john weru
Palliative care services into an existing oncology programme by john weru
 
Covering Cancer Treatments: Tricks of the Trade
Covering Cancer Treatments: Tricks of the TradeCovering Cancer Treatments: Tricks of the Trade
Covering Cancer Treatments: Tricks of the Trade
 
Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...Patient involvement in clinical research and long term conditions -what can b...
Patient involvement in clinical research and long term conditions -what can b...
 
ICTS Case Studies
ICTS Case StudiesICTS Case Studies
ICTS Case Studies
 
teamLift-ppt-v2
teamLift-ppt-v2teamLift-ppt-v2
teamLift-ppt-v2
 
Recruitment & Retention Plan: A Sample Strategy Presentation
Recruitment & Retention Plan: A Sample Strategy PresentationRecruitment & Retention Plan: A Sample Strategy Presentation
Recruitment & Retention Plan: A Sample Strategy Presentation
 
Site and Patient Engagement - Strategies for Improving Retention
Site and Patient Engagement - Strategies for Improving RetentionSite and Patient Engagement - Strategies for Improving Retention
Site and Patient Engagement - Strategies for Improving Retention
 
Health information Seminar - Dr Derick Mitchell - Oct 2017
Health information Seminar - Dr Derick Mitchell - Oct 2017Health information Seminar - Dr Derick Mitchell - Oct 2017
Health information Seminar - Dr Derick Mitchell - Oct 2017
 
Intro to residencies 2010
Intro to residencies 2010Intro to residencies 2010
Intro to residencies 2010
 
Cirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSION
Cirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSIONCirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSION
Cirriculum Vitae - Kenneth Smith 2016_PUBLIC VERSION
 

Semelhante a Rare disease stakeholder dynamics pmrg institute fall 2014

Kelly Clark
Kelly ClarkKelly Clark
Kelly ClarkOPUNITE
 
The Future of Market Access – The Patient Picture
The Future of Market Access – The Patient PictureThe Future of Market Access – The Patient Picture
The Future of Market Access – The Patient PicturePM Society
 
Generating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACOGenerating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACOTodd Berner MD
 
2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy
2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy
2014 Armada Presentation - Specialty Pharmacy at Retail PharmacyAvella Specialty Pharmacy
 
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
Rx15 treat wed_300_1_wilson-jarvis_2mendenhallRx15 treat wed_300_1_wilson-jarvis_2mendenhall
Rx15 treat wed_300_1_wilson-jarvis_2mendenhallOPUNITE
 
Enterpreneurial -Pharmaceutical-Marketing (Long Ming).pdf
Enterpreneurial -Pharmaceutical-Marketing (Long Ming).pdfEnterpreneurial -Pharmaceutical-Marketing (Long Ming).pdf
Enterpreneurial -Pharmaceutical-Marketing (Long Ming).pdfTimothyOlson20
 
Not All Meds Get Along: Reducing Inappropriate Medication Use
Not All Meds Get Along: Reducing Inappropriate Medication Use Not All Meds Get Along: Reducing Inappropriate Medication Use
Not All Meds Get Along: Reducing Inappropriate Medication Use Canadian Patient Safety Institute
 
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Canadian Organization for Rare Disorders
 
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...CompleteRx
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshOPUNITE
 
Soraya Ghebleh - Variation in Healthcare Delivery
Soraya Ghebleh - Variation in Healthcare DeliverySoraya Ghebleh - Variation in Healthcare Delivery
Soraya Ghebleh - Variation in Healthcare DeliverySoraya Ghebleh
 
Patient engagement in medication safety at the point of care – roles, respons...
Patient engagement in medication safety at the point of care – roles, respons...Patient engagement in medication safety at the point of care – roles, respons...
Patient engagement in medication safety at the point of care – roles, respons...Canadian Patient Safety Institute
 
Improving Healthcare Quality and Safety while Reducing Costs through Clinical...
Improving Healthcare Quality and Safety while Reducing Costs through Clinical...Improving Healthcare Quality and Safety while Reducing Costs through Clinical...
Improving Healthcare Quality and Safety while Reducing Costs through Clinical...UCLA CTSI
 
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCanadian Cancer Survivor Network
 
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's  2nd Pharmaceutical Managed MarketsHighlights from ExL Pharma's  2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's 2nd Pharmaceutical Managed MarketsExL Pharma
 

Semelhante a Rare disease stakeholder dynamics pmrg institute fall 2014 (20)

Kelly Clark
Kelly ClarkKelly Clark
Kelly Clark
 
The Future of Market Access – The Patient Picture
The Future of Market Access – The Patient PictureThe Future of Market Access – The Patient Picture
The Future of Market Access – The Patient Picture
 
Generating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACOGenerating Quality Data through Collaborative Research with an ACO
Generating Quality Data through Collaborative Research with an ACO
 
LHS Research vs Care
LHS Research vs CareLHS Research vs Care
LHS Research vs Care
 
2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy
2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy
2014 Armada Presentation - Specialty Pharmacy at Retail Pharmacy
 
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
Rx15 treat wed_300_1_wilson-jarvis_2mendenhallRx15 treat wed_300_1_wilson-jarvis_2mendenhall
Rx15 treat wed_300_1_wilson-jarvis_2mendenhall
 
Medication adherence
Medication adherenceMedication adherence
Medication adherence
 
Enterpreneurial -Pharmaceutical-Marketing (Long Ming).pdf
Enterpreneurial -Pharmaceutical-Marketing (Long Ming).pdfEnterpreneurial -Pharmaceutical-Marketing (Long Ming).pdf
Enterpreneurial -Pharmaceutical-Marketing (Long Ming).pdf
 
Not All Meds Get Along: Reducing Inappropriate Medication Use
Not All Meds Get Along: Reducing Inappropriate Medication Use Not All Meds Get Along: Reducing Inappropriate Medication Use
Not All Meds Get Along: Reducing Inappropriate Medication Use
 
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
 
Concepts of em
Concepts of emConcepts of em
Concepts of em
 
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
How High Will They Go? Managing Rising Drug Prices in a Changing Healthcare E...
 
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirshRx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
Rx15 treat tues_200_1_baxter_2barnes_3jeter_4kirsh
 
Soraya Ghebleh - Variation in Healthcare Delivery
Soraya Ghebleh - Variation in Healthcare DeliverySoraya Ghebleh - Variation in Healthcare Delivery
Soraya Ghebleh - Variation in Healthcare Delivery
 
Patient engagement in medication safety at the point of care – roles, respons...
Patient engagement in medication safety at the point of care – roles, respons...Patient engagement in medication safety at the point of care – roles, respons...
Patient engagement in medication safety at the point of care – roles, respons...
 
Improving Healthcare Quality and Safety while Reducing Costs through Clinical...
Improving Healthcare Quality and Safety while Reducing Costs through Clinical...Improving Healthcare Quality and Safety while Reducing Costs through Clinical...
Improving Healthcare Quality and Safety while Reducing Costs through Clinical...
 
How Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in CanadaHow Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in Canada
 
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptxCCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
CCSN Webinar Patient Input into HTA Decision Making Oct 5 2023.pptx
 
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's  2nd Pharmaceutical Managed MarketsHighlights from ExL Pharma's  2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
 
Choice & health..feb06
Choice & health..feb06Choice & health..feb06
Choice & health..feb06
 

Último

Turn Website Visits into Conversions (2).pdf
Turn Website Visits into Conversions (2).pdfTurn Website Visits into Conversions (2).pdf
Turn Website Visits into Conversions (2).pdfVWO
 
Music and Ai Technology
Music and Ai TechnologyMusic and Ai Technology
Music and Ai Technologyehimaibooks
 
Imposter Syndrome in Marketing & Why You're Not Alone
Imposter Syndrome in Marketing & Why You're Not AloneImposter Syndrome in Marketing & Why You're Not Alone
Imposter Syndrome in Marketing & Why You're Not AloneHerd
 
A navigation of two creative processes Study
A navigation of two creative processes StudyA navigation of two creative processes Study
A navigation of two creative processes Studystuwilson.co.uk
 
Ice Cream Brand Harmony Study - TINT Emotional Profiling Research
Ice Cream Brand Harmony Study - TINT Emotional Profiling ResearchIce Cream Brand Harmony Study - TINT Emotional Profiling Research
Ice Cream Brand Harmony Study - TINT Emotional Profiling ResearchTINT Marketing
 
Assignment 1 Task 1 - Apple's Marketing Mix slides
Assignment 1 Task 1 - Apple's Marketing Mix slidesAssignment 1 Task 1 - Apple's Marketing Mix slides
Assignment 1 Task 1 - Apple's Marketing Mix slideskatherinemiller93
 
Podvertise.fm - Podcast Advertising Marketplace - Startup Pitch Deck
Podvertise.fm - Podcast Advertising Marketplace - Startup Pitch DeckPodvertise.fm - Podcast Advertising Marketplace - Startup Pitch Deck
Podvertise.fm - Podcast Advertising Marketplace - Startup Pitch DeckNedko Nedkov
 
SVETLANA YONCHEVA Evolution of digital marketing.pdf
SVETLANA YONCHEVA Evolution of digital marketing.pdfSVETLANA YONCHEVA Evolution of digital marketing.pdf
SVETLANA YONCHEVA Evolution of digital marketing.pdfvikrs213
 
SEO Trends in 2024: What You Need to Know to Succeed
SEO Trends in 2024: What You Need to Know to SucceedSEO Trends in 2024: What You Need to Know to Succeed
SEO Trends in 2024: What You Need to Know to SucceedMumbai Pixels
 
Product Demo: HubSpot's Coolest AI Tools for B2B Tech Companies
Product Demo: HubSpot's Coolest AI Tools for B2B Tech CompaniesProduct Demo: HubSpot's Coolest AI Tools for B2B Tech Companies
Product Demo: HubSpot's Coolest AI Tools for B2B Tech CompaniesKiwi Creative
 
The Creative Marketing campaigns of WeRoad
The Creative Marketing campaigns of WeRoadThe Creative Marketing campaigns of WeRoad
The Creative Marketing campaigns of WeRoadFabio Bin
 
Digital Marketing PPT.pptx(PPT related the Digital marketing)
Digital Marketing PPT.pptx(PPT related the Digital marketing)Digital Marketing PPT.pptx(PPT related the Digital marketing)
Digital Marketing PPT.pptx(PPT related the Digital marketing)digitalwithalok1
 
Cricket Playbook for Growth Marketers: Adjust x Glance report
Cricket Playbook for Growth Marketers: Adjust x Glance reportCricket Playbook for Growth Marketers: Adjust x Glance report
Cricket Playbook for Growth Marketers: Adjust x Glance reportSocial Samosa
 
State_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdf
State_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdfState_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdf
State_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdfUreka Media Vietnam CO., LTD
 
Digital Marketing Ultimate Guide 2024.pdf
Digital Marketing Ultimate Guide 2024.pdfDigital Marketing Ultimate Guide 2024.pdf
Digital Marketing Ultimate Guide 2024.pdfaptomark
 
Dhanuka Agritech Limited - Sales and Marketing Intern
Dhanuka Agritech Limited - Sales and Marketing InternDhanuka Agritech Limited - Sales and Marketing Intern
Dhanuka Agritech Limited - Sales and Marketing Internrisabhpandeyconnect
 
Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...
Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...
Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...Opus Momentum
 
Run more experiments with fewer resources
Run more experiments with fewer resourcesRun more experiments with fewer resources
Run more experiments with fewer resourcesVWO
 
best digital marketing company in south delhi
best digital marketing company in south delhibest digital marketing company in south delhi
best digital marketing company in south delhifirstpointcreationsa
 
SEO BIGGENER SLIDE complete guide fresher
SEO BIGGENER SLIDE complete guide fresherSEO BIGGENER SLIDE complete guide fresher
SEO BIGGENER SLIDE complete guide freshertanoojee71
 

Último (20)

Turn Website Visits into Conversions (2).pdf
Turn Website Visits into Conversions (2).pdfTurn Website Visits into Conversions (2).pdf
Turn Website Visits into Conversions (2).pdf
 
Music and Ai Technology
Music and Ai TechnologyMusic and Ai Technology
Music and Ai Technology
 
Imposter Syndrome in Marketing & Why You're Not Alone
Imposter Syndrome in Marketing & Why You're Not AloneImposter Syndrome in Marketing & Why You're Not Alone
Imposter Syndrome in Marketing & Why You're Not Alone
 
A navigation of two creative processes Study
A navigation of two creative processes StudyA navigation of two creative processes Study
A navigation of two creative processes Study
 
Ice Cream Brand Harmony Study - TINT Emotional Profiling Research
Ice Cream Brand Harmony Study - TINT Emotional Profiling ResearchIce Cream Brand Harmony Study - TINT Emotional Profiling Research
Ice Cream Brand Harmony Study - TINT Emotional Profiling Research
 
Assignment 1 Task 1 - Apple's Marketing Mix slides
Assignment 1 Task 1 - Apple's Marketing Mix slidesAssignment 1 Task 1 - Apple's Marketing Mix slides
Assignment 1 Task 1 - Apple's Marketing Mix slides
 
Podvertise.fm - Podcast Advertising Marketplace - Startup Pitch Deck
Podvertise.fm - Podcast Advertising Marketplace - Startup Pitch DeckPodvertise.fm - Podcast Advertising Marketplace - Startup Pitch Deck
Podvertise.fm - Podcast Advertising Marketplace - Startup Pitch Deck
 
SVETLANA YONCHEVA Evolution of digital marketing.pdf
SVETLANA YONCHEVA Evolution of digital marketing.pdfSVETLANA YONCHEVA Evolution of digital marketing.pdf
SVETLANA YONCHEVA Evolution of digital marketing.pdf
 
SEO Trends in 2024: What You Need to Know to Succeed
SEO Trends in 2024: What You Need to Know to SucceedSEO Trends in 2024: What You Need to Know to Succeed
SEO Trends in 2024: What You Need to Know to Succeed
 
Product Demo: HubSpot's Coolest AI Tools for B2B Tech Companies
Product Demo: HubSpot's Coolest AI Tools for B2B Tech CompaniesProduct Demo: HubSpot's Coolest AI Tools for B2B Tech Companies
Product Demo: HubSpot's Coolest AI Tools for B2B Tech Companies
 
The Creative Marketing campaigns of WeRoad
The Creative Marketing campaigns of WeRoadThe Creative Marketing campaigns of WeRoad
The Creative Marketing campaigns of WeRoad
 
Digital Marketing PPT.pptx(PPT related the Digital marketing)
Digital Marketing PPT.pptx(PPT related the Digital marketing)Digital Marketing PPT.pptx(PPT related the Digital marketing)
Digital Marketing PPT.pptx(PPT related the Digital marketing)
 
Cricket Playbook for Growth Marketers: Adjust x Glance report
Cricket Playbook for Growth Marketers: Adjust x Glance reportCricket Playbook for Growth Marketers: Adjust x Glance report
Cricket Playbook for Growth Marketers: Adjust x Glance report
 
State_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdf
State_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdfState_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdf
State_of_MarTech_Not_just_another_report_it_s_a_panoramic_tour_of_the_.pdf
 
Digital Marketing Ultimate Guide 2024.pdf
Digital Marketing Ultimate Guide 2024.pdfDigital Marketing Ultimate Guide 2024.pdf
Digital Marketing Ultimate Guide 2024.pdf
 
Dhanuka Agritech Limited - Sales and Marketing Intern
Dhanuka Agritech Limited - Sales and Marketing InternDhanuka Agritech Limited - Sales and Marketing Intern
Dhanuka Agritech Limited - Sales and Marketing Intern
 
Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...
Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...
Opus Momentum - Data Driven and AI Enabled Digital Marketing Agency | Company...
 
Run more experiments with fewer resources
Run more experiments with fewer resourcesRun more experiments with fewer resources
Run more experiments with fewer resources
 
best digital marketing company in south delhi
best digital marketing company in south delhibest digital marketing company in south delhi
best digital marketing company in south delhi
 
SEO BIGGENER SLIDE complete guide fresher
SEO BIGGENER SLIDE complete guide fresherSEO BIGGENER SLIDE complete guide fresher
SEO BIGGENER SLIDE complete guide fresher
 

Rare disease stakeholder dynamics pmrg institute fall 2014

  • 1. 1 Rare Disease Stakeholder Dynamics Paul Allen Camm Epstein
  • 3. Definition of a rare disease: <200,000 Americans Number of rare diseases: >6,800 Americans with a rare disease: 25-30 million NIH Office of Rare Disease Research http://rarediseases.info.nih.gov/about-ordr/pages/31/frequently-asked-questions 3 11/12/2014
  • 4. Rising prices, additional options and increasing use of combination therapy drive costs higher. 11/12/2014 Before: High $ * Very Low Vol = Low $ After: High $ * Low Vol = Medium $
  • 5. Specialty medications are growing in absolute dollars and percent of drug spend $235 billion (50%) 2018 $92 billion (30%) 2012 CVS Caremark, Insights 2014 http://info.cvscaremark.com/insights2014/INSIGHTS%20Trend%202014-v2.pdf 5 11/12/2014
  • 7. Physicians Pulmonary Arterial Hypertension Payers Patients Payers Physicians Cystic Fibrosis Patients Physicians Hereditary Angiodema Payers Patients
  • 9. • Want to feel better, improved quality of life – Fewer symptoms of condition and fewer side effects of therapy – Easier to administer products • Willing to make tradeoffs between efficacy and convenience • Cost is often not a concern – Depends upon coverage, needs/wants and disposable income • PAPs and charitable foundations typically address any financial difficulties • Very well-informed – Often better informed than physicians not specializing in the condition • Share information with and supportive of other patients • Often emotional – Life-threatening – Familial impacting multiple family members 9 Patients
  • 10. Physicians • Appeal denials when necessary • Test and treat aggressively • Prefer to prescribe proven therapies – Yet, sensitive to patient preferences • Receptive to tradeoffs between efficacy and improved QOL 10
  • 11. Nurses • Work through patient assistance programs • Provide most patient education • Work through most access issue 11
  • 12. Payers • They generally do not manage rare conditions aggressively, but… – Willing to select preferred products, increase restrictions and contract when there are multiple, poorly differentiated options • Especially when there are large cost differences and/or multiple options in the same class • Willing to relax, but not abandon, requirements for evidence • Encourage care delivered outside of centers and discount ‘center of excellence’ designations – Especially when there is a lack of evidence • Encourage use of oral formulations – Particularly when the costs are similar • Discourage use of combination therapy – Particularly when there is a lack of evidence • Critically evaluate clinical guidelines/consensus statements – Reject those not based on evidence • Frustrated by manufacturer pricing 12
  • 13. Medical Societies • Develop consensus statements/clinical guidelines • Advocate what they believe to be appropriate care – Cost-effective care is an emerging consideration 13
  • 14. Manufacturers • Charge high prices for some therapies – Particularly when the target patient population is very small – Particularly when there is a genetic marker • Find it difficult to enroll sufficient numbers of patients in clinical trials • Very supportive of Patient Assistance Programs (PAPs) – Work hard to ensure patient out-of-pocket costs are not a barrier for those unable to pay 14
  • 15. Purchasers • Watching specialty pharmacy spend rise • Asking for tighter controls – Want to avoid negative public relations • Shifting costs to patients 15
  • 16. Advocacy Organizations • Celebrate the entry of new options – Interpret new entrants as a sign of progress towards a cure • Supporting clinical guideline/consensus statement development • Supporting center of excellence designations 16
  • 18. • Share intense bonds – Often social, informal relationships “I feel like they are family” • Frequent and sometimes long conversations – Patients ask questions and make requests 18
  • 19. 19 • Regularly bringing diverse stakeholders together • Facilitating dialogue and collaboration
  • 21. 21 Access Restrictions Multiple Therapies Combination Therapy Multiple Drugs in Same Class Prescribing by non-KOLs Payer Preferences Multiple Routes of Administration Patient Preferences Physician Preferences Efficacy Safety Cost Patient Costs Diffusion of Care Sites Oral Therapies Centers of Excellence Designations Public Relations Very Low Prevalence Significant Unmet Needs Awareness/ Knowledge Consensus Statements/Clinical Guidelines Earlier Diagnosis/Treatment Better Outcomes Increased Utilization Higher Drug Prices Growing Spend/Trend Clinical Trial Enrollment Difficulties Lack of Comparative Effectiveness Research Reliance on Patient Assistance Enhanced Role of Nurses Patient-Physician Conversations Hope Benefit Design Patient-Provider Relations
  • 23. • Halo effect across rare conditions – Acceleration towards access restrictions tipping points • Debate and research on oral therapies – Cost-effectiveness – Patient preferences • New methods for studying combination therapies 23
  • 24. • Patient registries to aggregate experience • Growth in supply of and demand for patient assistance • Enhanced social media and collaboration capabilities – Enriching interpersonal communications 24
  • 26. • Success in crowded markets – Novel mechanisms of action – Improved ROA differentiation – Genetic markers/companion diagnostics – Premium pricing that is justified and sustainable • Price reductions when indications expand 26
  • 27. • Success in new markets – New therapies – Sufficient unmet need to yield ROI 27
  • 28. Currant Insights, LLC 33 East Avenue Saratoga Springs, NY 12866 Camm Epstein Managing Director (518) 429-0875 camm@currantinsights.com Olson Research Group, Inc 1020 Stony Hill Road, Suite 300 Yardley, PA, 19067 Paul Allen Executive Vice President (215) 499-0244 pallen@olsonreserchpa.com

Notas do Editor

  1. These costs are now on purchasers’ and payers’ radar screens
  2. Specialty medications are the fastest-growing - and the most expensive - segment of pharmacy care.
  3. Comprehensive solution, features
  4. Many patients avoid infused therapy The desire to avoid IV is so intense, that many relax their informational needs/wants and will try unproven therapies and mechanisms of action with preferred routes of administration
  5. When dealing with payers, nurses are typically on the ‘font lines’
  6. Denying combination therapy lacking evidence is driven by efficacy, safety and cost concerns – Payers do not want members to be guinea pigs Some payers have been frustrated with the markup some specialty pharmacy providers have been charging
  7. By definition, the universe is small Hard to find patients that meet the inclusion criteria Patients may be reluctant to switch – concerns about getting covered if the need/want to switch back, may be experiencing success with current therapy
  8. Many have close social relationship with one another
  9. Here’s a model of how many of the dynamics among stakeholders are interrelated for rare diseases.